Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Portfolio Pulse from Benzinga Newsdesk
Can-Fite BioPharma Ltd. has expanded its out-licensing agreement with Ewopharma AG to include the pancreatic cancer indication of its proprietary small molecule drugs. This expansion could potentially enhance the value of Can-Fite's oncology pipeline by addressing a new therapeutic area.
January 30, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The expansion of Can-Fite's licensing deal with Ewopharma to include pancreatic cancer could increase the potential revenue and market reach for Can-Fite's drugs, positively impacting investor sentiment.
The news of expanding an out-licensing deal to include a new indication, such as pancreatic cancer, is typically seen as positive for a biotech company. It suggests confidence in the drug's potential and may lead to increased revenue from licensing fees or royalties. This could positively influence Can-Fite's stock price in the short term as investors may anticipate future growth from this expanded deal.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100